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The importance and long-term consequences
of skin sensitization due to topical therapeutic
agents has been stressed for some time. In
particular, the high frequency of intolerance to
the "para group" has been described following
sensitization to sulfa preparations. Lately, the
problem of sensitization to the thiazine nucleus
has arisen because of the many cases of sensitiza-
tion to Phenergan cream and the numerous new
products belonging to this chemical group which
are now being marketed. However, among anti-
biotics up to now there has been little in the way
of precise evidence for cross-sensitization. Be-
cause of the dangers inherent to sensitization we
had always sought to use for topical therapy
antimicrobial substances which would not be also
administered parenterally. Neomycin has there-
fore gained considerable importance in derma-
tological therapy, being a potent antibiotic a
rare sensitizer and seldom used internally.
reactions of irritation showed up, but skin testing
was negative on these patients. It was only after
re-applying neomycin in patients treated with it
several months previously that a number of cases
of sensitization appeared. These reactions seemed
to us to be of limited general importance due to
their small number. However, they had to be
kept in mind because of the numerous forms
under which neomycin was being used and
marketed (such as eye drops, ear drops, intestinal
medication and more recently for pulmonary
insufflation); in addition, a closely related anti-
biotic, framycetin sulfate, was being put on the
market. Patients sensitized to neomycin had to
be cautioned against the use of all these prepa-
rations.
During the study of a case of eczema due to
contact with neomycin it was found that this
patient had become extremely sensitive to
streptomycin. A detailed history of this case
TABLE I
Summary of Patients Tested
Patch Tests
Patient Histoly Reaction to Treatment
Neomycin Streptomycin
F. C. Neomycin compresses
(retreatment)
Acute spread of eczema +++ ++++
H. M. Neomycin compresses
(retreatment)
Acute spread of eczema ++ +++
B. G. Neomycin compresses
(retreatment)
Acute spread of eczema ++ +++
J. Y. Neomycin unguent and
streptomycin i.m
Anaphylactoid and ec-
zema
Not tested Not tested
F. T. Sensitivity to antibiotics +++ +++*
V. M. Sensitivity to antibiotics ++ +++*
F. A. (Nurse) Handles streptomycin Hand eczema ++' +++
H. S. (Nurse) Handles streptomycin Face and hand eczema ++e +++
* No known previous contact
During the first year of use of neomycin in our
service no sensitizations were found. A few
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revealed no previous contact to streptomycin and
it was therefore decided to test all further cases
sensitized to neomycin or streptomycin with
both of these compounds. It was found that
patients sensitized to either one of them are
regularly sensitive to the other.
Up to the present time we have only a limited
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series of eight such cases. However, due to the
importance of cross-sensitization of this nature,
we are presenting these findings. A summary of
the data pertaining to these eight cases is given in
Table I. Of these eight patients with positive
patch tests to both antibiotics five had never had
contact with streptomycin as far as could be
ascertained by careful history taking. Two
patients had no known contact with neomycin
but had been handling streptomycin. One
patient had contact with both antibiotics and
reacted with an anaphylactoid response to an
intramuscular injection of streptomycin, followed
by eczematization of the neomycin treated area.
In every case the reaction to streptomycin was
markedly more positive than that to neomycin.
Neomycin:
Neamine
H H
H H
112N NH2
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FIG. 1
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In a number of instances, ordinary patch
testing was insufficient to elicit a reaction. How-
ever, light scarification of the area prior to testing
regularly yielded positive results in sensitized
patients. This is in accord with a recent article by
Epstein (1) who found intradermal testing neces-
sary to elicit positive reactions to neomycin.
Intradermal tests were not performed by us
because of the previous occurrence of a severe
accident in a streptomycin sensitive patient
being tested intradermally (2).
DISCUSSION
Neomycin, obtained from &reptomyce8 fradiae,
is a mixture of nearnine and two glucosides of this
substance. Framycetin, obtained from Strepto-
myces lavendulae, is another neamine glucoside.
The common neamine moiety is a cyclohexane
bearing two amino groups (Fig. 1).
The glucide fractions of neonlycin B, C, and
framycetin are probable biases bearing an amino
group. At the present time in France the com-
mercially available form of neomycin is prac-
tically pure neomycin B. The formula for strepto-
mycin is shown in Fig. 2, and also consists of a
substituted cyclohexane (streptidine) linked to an
amino-substituted biose (streptobiosamine).
The chemical configuration causing cross-
sensitization between neomycin and streptomycin
is likely to be found in the aglycone moieties, but
Sire piomycin: H OH
H H
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CROSS-SENSITIZATION BETWEEN NEOMYCIN AND STREPTOMYCIN 227
the exact chemical group responsible for this
phenomenon has not been ascertained. Both or
either of the amino-cyclohexane and biosamine
fractions may be implicated.
A word now about the clinical aspects of this
work. The type of reaction seen after topical
sensitization to antibiotics seems to be somewhat
different than that expected in the usual allergic
contact dermatitis. Instead of an acute vesicular
oozing process at the site of contact the reaction
is more often of the dry desquamative spreading
type which may at times involve covered areas
more suggestive of atopic dermatitis.
In addition, the necessity for scratching the
skin area to be patch tested in order to obtain
reproducible results seems to indicate a deeper
site of reaction than in the usual contact derma-
titis. Both of these facts have also been pointed
out by Epstein (1).
In examining the figures on dermatitis due to
therapeutic agents observed in our clinic over the
past ten years, it was found that between 1947
and 1949 the sulfa compounds caused 41% of
these eruptions; by 1953, the antihistamine
creams were causing 50% of the reactions.
Recently the antibiotics have come to the fore to
constitute the main cause of contact dermatitis
due to therapeutic agents during 1956.
The importance of these sensitizations is
obvious considering the many important uses of
these substances. The number of cases of cross-
sensitization between neomycin and streptomycin
reported here is small. Investigation of similar
cases by other workers should yield important
data.
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DISCUSSION
DR. CLARENCE S. LIVIN000D (Detroit, Michi-
gan): I am very much interested in this paper
because for some time now we have been ac-
cumulating a series of patients who have
evidently been sensitized to neomycin by the
prolonged topical application of the antibiotic,
particularly in patients with eczematized
dermatitis. We have been impressed by the fact
that often it is not easy to recognize these re-
actions. Dr. Stephan Epstein is of the same
opinion (Epstein, Stephan: "Contact Derma-
titis from Neomycin Due to Dermal Delayed
(Tuberculin-Type) Sensitivity," Dermatologica
113: 191, 1956). We have been disturbed by the
fact that these reactions seem to persist for a
more prolonged period than is usual for contact
sensitivity reactions due to many other medica-
ments. In performing patch tests on many of
these patients, there has been a tendency in a
few cases for positive reactions to appear as long
as 4 or 5 days after application rather than
within a period of 24 to 48 hours, and in some
instances, the positive patch tests have per-
sisted for as long as several months.
When I saw this paper listed on the program
several months ago I asked two of my colleagues
(Dr. Robert Fosnaugh and Dr. Hugh Reynolds)
to test a group of these patients with apparent
sensitivity to neomycin with both streptomycin
and neomycin. Unfortunately due to a mis-
understanding, only intradermal tests were done
in the case of streptomycin whereas both
intradermal tests and patch tests were done with
neomycin. In a small series of 15 patients with
positive patch and intradermal tests to 1:100
aqueous solution of neomycin, 4 were found to
have a positive intradermal test to 1:100 aqueous
solution of streptomycin; all of these patients
were also tested intradermally to dihydro-
streptomycin and in each case the reaction was
negative. We are not able to interpret the pos-
sible significance of this observation and ob-
viously this whole subject requires further study.
In our daily practice, we find it rewarding to
review carefully the previous medication of
patients with chronic eczematous dermatitis
with particular reference to the previous use of
combinations of hydrocortisone and neomycin.
In some of these patients we have found that the
discontinuation of such therapy followed by the
appropriate use of plain hydrocortisone topical
application results in improvement and control
of the eczematous process despite the fact that
the previous combined hydrocortisone-nea--
mycin ointment or lotion did not seem to cause
an obvious contact dermatitis.
It seems most important to extend these
studies on cross-sensitization reactions to neo-
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mycin and streptomycin because if a significant
percentage of patients are sensitized to strepto-
mycin by the topical application of neomycin, it
is of obvious significance.
DR. SAMUEL M. PECK (New York, N. Y.):
This thought-provoking paper I think will
again lead us to re-evaluate our interpretation
of skin testing for antibiotic sensitivity.
Now that the research on penicillin sensitivity
has fallen so far into the background, I am
afraid that we are forgetting some of the basic
data which was demonstrated at that time.
Many problems were left unanswered and I am
glad to note that the authors have revived some
of puzzles which arose at that time. No. 1, what
is the relationship between an intradermal test
with penicillin in a patient sensitive to penicillin
to the patch test with the same material? Years
go it was shown that in patients with eczematoid
richophytids one could obtain a positive patch
test to trichophytin. In other types of "ids",
this was not the case. What is the status in skin
eruptions due to penicillin sensitivity? You get a
positive penicillin test whether the patient has an
eczematous vesicular type of eruption on the
hands and feet or whether they have an erythema
multiforme type, or urticarial type of eruption.
A positive patch test to penicillin is rare and only
when there is a high degree of sensitivity to
penicillin even in non-eczematous eruptions.
This data should be reviewed and the work
repeated. It is my feeling that even the so-called
positive patch test to an antibotic or to tn-
chophytin and even tuberculin gives histo-
logic picture which differs from the true patch
test to simple chemicals in contact dermatitis.
It has never been explained to my satisfaction
why a patient with T. purpureum infection may
show only an immediate reaction to tricho-
phytin. Yet the same antigen is present to give
a typical delayed reaction in a patient with
trichophytids.
The point I wish to stress here is this, that we
have to reevaluate our results, of skin testing with
antibiotics. They can be used to some extent not
only to indicate the degree of sensitivity but
what is more important perhaps is to predict the
type of allergic response and its severity in the
sensitive patient.
DR. ALEXANDER A. FISHER (Long Island,
N. Y.) : At the Skin and Cancer Unit we have been
also finding increasing numbers of patients who
have become sensitive to neomycin. In a series of
100 consecutive patients, three became sen-
sitized to neomycin. In all of these patients we
obtained a positive patch test without doing the
preliminary scratch procedure. Two of the
patients had the so-called "subtle type" of
contact dermatitis which did resemble dry
atopic eczema. The other patient had a frank
type of contact dermatitis. After I had read the
protocol on the paper presented just now, we
tested these three patients with streptomycin
and found that one patient also reacted to
streptomycin.
Incidentally in 300 consecutive patients who
used aureomycin ointment, only one showed a
sensitivity to aureomycin. That patient did not
react to aureomycin given internally. In 100
consecutive patients who used terramycin, there
were no sensitivity reactions. In view of the fact
that neomycin may cause cross-reactions with
streptomycin, and in view of the fact that we
have the impression that neomycin is not as
efficient as aureomycin and terramycin, we
wonder why neomycin should be used at all.
Dn. RUDOLF L. BARR (New York, N. Y.):
Dr. Sidi and his group previously have made
notable contributions in the field of cross-
sensitization and he and his group should be
congratulated on this beautiful new piece of
work.
When Dr. Ludwig and I first published a case
of allergic eczematous sensitivity to neomycin
(Ann. of Allergy, 10: 136, 1952) there was
surprise because at that time neomycin was
thought to be either non-allergenic or to have an
exceedingly low degree of allergenicity. What we
have heard today about sensitization to neo-
mycin confirms what has been observed with the
use of many other new topical medicaments;
substances which in the beginning appear to
have a very low sensitizing index later on when
they are more widely used, prove to have a much
higher sensitizing index than was expected. The
reasons for this are too obvious to necessitate
detailing before this audience.
As far as the clinical features of neomycin
dermatitis are concerned, I can confirm Dr. A. A.
Fisher's statement that some patients develop
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an acute vesicular, allergic, eczematous contact
type of dermatitis of the usual type. In many
other eases, however, the eruption takes on the
appearame described by the presenters and
several of the discussers.
It is most interesting to reflect upon the reasons
which led to preferential use of neomycin over the
tetracycline group compounds as topical medica-
ments on the part of many dermatologists. As far
as I know neomycin became so popular as a
topical medicament principally for 3 reasons:
1) it has an excellent spectrum of antibacterial
activity; 2) it was thought to have a very low
allergenicity and 3) it was not being used or
hardly was used systemically. On the other hand
topical application of the tetracycline group
compounds was considered to be perhaps some-
what risky, because allergic sensitization after
topical use might interfere with their systemic use
later on. Experience has shown that the tetra-
cycline group compounds have a very low
eczematogenic sensitizing capacity indeed and
their topical use has not interfered to any sig-
nificant extent with their systemic administra-
tion. Except for their yellowish staining proper-
ties I prefer these compounds to neomycin as
topical medicaments.
DR. IRA L. SCHAMBERO (Philadelphia, Pa.):
I have under my care at present a nurse with
contact dermatitis due to streptomycin. A
member of the Pennsylvania Occupational
Disease Board who called me concerning this
patient's request for compensation stated that
dermatitis due to common or frequent sen-
sitizers is compensable whereas dermatitis caused
by a substance which only rarely sensitizes is not.
This seems to me a very curious legal concept.
DR. JEAN HEwrrr (Paris, France): I was
greatly interested in this paper. It is many
years that I know I follow the works of Sidi and
his colleagues. I believe we will see more and
more cases of cross-sensitization of the type
because the chemical formulae of products which
are used have sometimes a common part. We
think too that it is generally said that neomycin
is a very useful topical medicament because this
kind of cross-sensitization is above all theo-
retically useful to know in practice. It will
certainly give a few cases of cross-sensitization
and eczematoid sensitization. But the fact we
think that it will produce a few cases of this type
should be kept in mind.
Da. R. L. MAYER (Summit, N. J.): Dr.
Sidi's paper is very interesting and thought-
provoking indeed. The importance of the problem
of cross-sensitization lies not only in the practical,
but also in the theoretical, aspects. Its practical
importance is evidenced by its general medical
significance, as well as by the fact that the FDA
now requires appropriate tests to eliminate
strong sensitizers, in particular among com-
pounds intended for topical use. Unfortunately,
we do not yet possess an adequate test which
would permit the prediction of possible sensitizers
of the immediate and anaphylactic type among
drugs.
Within this cross-reaction, mentioned in
Sidi's paper, neomycin seems to be considerably
less sensitizing than streptomycin. I have de-
scribed similar cases in the antigenic group of
azo dyes, and the question arises why, within
groups of closely related and cross reacting sub-
stances, certain compounds are strong, others
only weak sensitizers, and others only elicitors.
There may be many reasons for this, such as
differences in exposure, differences in the mode of
application, differences in solubility, rapidity of
elimination, chemical stability, etc. One of the
most important factors is the chemical nature of
the carrier to which the sensitizing substances
become attached within the body. All cross-
reacting compounds of low molecular weight are
haptens which acquire sensitizing properties
only after they have been attached to a suitable
carrier to form antigenic substances of high
molecular weight. It is generally assumed that
the carriers to which haptens become attached
do not play any active role in the process of
sensitization. This seems to me not correct, and I
have lately drawn attention to the fact that, on
the contrary, the type of sensitization seems very
much dependent upon the chemical and physical
nature of the carrier (globular or fibroid protein,
ground substance, lipopolysaccharides). Other
factors explaining the differences in the ability to
sensitize may be differences in the way various
substances, even chemically closely related,
combine with the carrier.
Dr. Peck's question why a compound in-
jected intradermally will produce another type of
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sensitization than a compound applied upon the
skin, may be answered as follows: The carriers
with which the hapten will combine upon
epidermal application and intradermal injection
are different. In the first case there are only
keratinic and collagenic substances involved;
in the second case, ground substances and
globular protein.
Da. MABEL G. SILVERBERG (New York,
N. Y.): Except for special experimental purposes,
as was the case in this work, it is very undesirable
to scarify the skin before a patch test since
scarifying the skin increases the danger of
sensitizing the skin by the patch test itself.
DR. ALBERT M. KLIoN (Philadelphia, Pa.):
I think this originally neomycinophilic audience
is being rapidly converted into a neomycino-
phobic one. As a neomycin lover I wish to defend
the assault on this compound. I think it is almost
inevitable that some instances of sensitization
will be encountered when the use of an agent
becomes widespread enough. Tons of neomycin
ointment are being applied to skin annually. For
years there was scarcely a whisper—now comes a
sudden clamor that neomycin may be a strong
sensitizer. We have been through this precise
situation before with other agents. Neomycin is
a splendid surface disinfectant and I hardly think
it sensible to forego its use just because a few
cases of sensitization have at last turned up.
DR. VINCENT J. DERBES (New Orleans, La.):
I would like to comment about the remark that
Dr. Schamberg made about compensability. I
think his committee in his state of Pennsylvania
is basing its decision on the law, not on what
physicians would regard as logic. The law states,
and many cases come to trial before com-
missions, that a substance which causes nsi-
tivity only rarely, cannot be charged to the
manufacturer or seller of that commodity. Thus
in the case of Frankes v. Bennett (146, S.W. 2d.
163 Arkansas) it has been ruled that "it is com-
mon knowledge that many people are allergic to
particular foods and cannot eat them no matter
how pure nor how well prepared." Again, in
Barrett v. Kresge (19A. 2d. 502, 144 Pa. Super.
516) the ruling stated that the dermatitis which
a buyer suffered after wearing a dress was due to
her individual allergic nature, instead of to the
character of the dye, and that the dye in the dress
would not have harmed a normal person. The
seller of that dress was not liable under the Sales
Act relating to implied warranty of fitness. In
Kroger v. Industrial Commission (Wis. Supreme
Ct. decided 1/13/42) the appellant contended
that the law was not intended to cover every
allergic tendency of certain sensitized indi-
viduals to certain substances. That is the reason
for the decision.
Dn. HERMANN PIE1us (Monroe, Michigan):
Since Dr. Stephan Epstein is not here, and since I
had the privilege of examining all his histological
preparations, I would like to point out that the
response to patch tests with neomycin, at least
in those cases that Dr. Epstein biopsied is not
eczematous. One may find some small vesicles in
the epidermis. These are around the sweat ducts
which probably permit the drug to penetrate
deeper into the skin. Most of the reaction is of the
dermal type of contact sensitivity about which
Dr. Epstein has written lately.
He confused me greatly several times with his
biopsies when he did not give me the history. I
was tempted to diagnose lymphoblastoma rather
than dermatitis. It looks like reaction of the
reticulo-endothelial system rather than the
leukocytic, inflammatory reaction that we expect
to find in contact dermatitis.
The second point I would like to make is this.
Even though the rate of sensitivity to neomycin
is probably very low and may not have gone up
as Dr. Kligman said, I think the practical
important thing is the insidiousness of the clinical
manifestations which are not easily recognized as
contact sensitivity by the physician who is not
aware of this type of reaction. Neomycin allergy
manifests itself often only as a prolongation of the
course of the disease that is being treated. This is
particularly true with the present use of the drug
together with hydrocortisone, because the hydro-
cortisone then blunts the inflammatory reaction.
One may see only that the patient does not get
well and may not consider that the neomycin is
keeping his disease going, unless he is aware of
this peculiar type of sensitivity.
DR. CYRIL MARCH (in closing): I want to thank
the discussers in Dr. Sidi's name for the many
comments and for the confirmation that they
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have offered for most of the points in this com-
munication. I am also very glad that Dr. Mayer
answered Dr. Peck's question in such a clear
way. His comments open the way to many
avenues of research.
Dr. Livingood and Dr. Fisher comment on the
fact that they were able to demonstrate sen-
sitivity to neomycin by conventional patch
testing in their series. It is probable that a
number of patients who were negative on patch
testing would have given positive reactions with
the scarification procedure. Some of the patients
in Dr. Sidi's small series did react positively to
patch tests but the others would have been
missed, had scarifying not been performed.
As to Dr. Silverberg's comment on the dangers
of scarifying the skin prior to patch testing, I
have no comment. I don't know about it.
